Press Releases

June 2026 - IBSA Foundation Fellowships Shatter Records with Unprecedented Global Reach and Opens 2026 Call

May 2026 - IBSA announces the passing of its President and CEO, Arturo Licenziati

April 2026 - IBSA UK&I assumes direct commercial responsibility for ialuril® in the UK and Ireland

March 2026 - IBSA UK&I Celebrates its Historic Debut at ACE 2026, Winning the Prestigious “Injectable Product of the Year” Award for Profhilo® Structura

February 2026 - IBSA UK&I launches Perovial®: the first licensed injectable option for men with acute Peyronie’s disease

February 2026 - IBSA UK launches Hyaluxelle®: a new non-hormonal, injectable option for vulvovaginal atrophy (VVA) associated with genitourinary syndrome of menopause (GSM)